Biotech giants square off in 'biosimilar' fight for top-selling cancer drug
Biotech titans Genentech Inc. and Amgen Inc. are going head-to-head over the $7 billion cancer-fighting drug Avastin.
Genentech, the South San Francisco-based U.S. biotech unit of Swiss drug giant Roche, filed a suit Thursday in U.S. District Court in Delaware that could delay Amgen's lower-cost biosimilar version of Genentech's best-selling drug. It claims Amgen has obstructed it from evaluating ahead of a March 24 deadline whether any of its patents are infringed by Amgen's copy.
If Genentech…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Avastin | Biotechnology | Cancer | Cancer & Oncology | Health Management | Legislation